Current Headlines

  1. Omeros Announces Completion Of IgA Nephropathy Cohort In OMS721 Phase 2 Clinical Trial
    5/17/2017

    Omeros Corporation recently announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders

  2. Kemwell Biopharma Supplies Biologics Drug Substance For Phase 1 Clinical Trials For US IND Filing
    5/17/2017

    Kemwell Biopharma, a contract development and manufacturing service provider, announced today that it has manufactured and supplied drug substance using its state-of-the-art mammalian cell culture plant in India for clinical trials that will be performed by its customer in USA for an IND filing

  3. FDA Grants Bayer Priority Review For Investigational Compound Copanlisib In Follicular Lymphoma
    5/17/2017

    Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for copanlisib for the treatment of relapsed or refractory follicular lymphoma (FL) patients who have received at least two prior therapies

  4. AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis
    5/17/2017

    AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data from two replicate Phase 3 studies evaluating the efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with endometriosis, will be presented at the 13th World Congress on Endometriosis in Vancouver, Canada. New data highlighting the effects of two different elagolix doses and dosing regimens on ovarian sex hormones and ovulation will also be presented

  5. Specialised Therapeutics Asia To License Promising Anti-Cancer Compound Lurbinectedin (PM1183) For South East Asia, Australia And New Zealand
    5/17/2017

    International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) is set to commercialise a promising new anti-cancer drug throughout South East Asia, after signing a second major licensing deal with European pharmaceutical company PharmaMar

  6. X-Chem And Vertex Enter Into Multi-Target Genetic Disease Collaboration
    5/16/2017

    X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, recently announced a collaboration with Vertex Pharmaceuticals Incorporated

  7. BioAtla And Sinobioway Expand Collaboration Agreement And Enter Into Services Agreement
    5/16/2017

    BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that BioAtla and Beijing Sinobioway Group Company, Limited (Sinobioway) expanded their CAB development and commercialization collaboration agreement with the addition of five new CAB antibody targets and entered into a new services agreement for Sinobioway to provide specified development and manufacturing services to BioAtla

  8. Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
    5/16/2017

    Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SB-525, the Company's clinical stage cDNA gene therapy candidate for hemophilia A, which is being developed as part of an exclusive, global collaboration and license agreement with Pfizer Inc. (NYSE: PFE)

  9. Ignyta Granted Breakthrough Therapy Designation For Entrectinib By U.S. Food And Drug Administration
    5/15/2017

    Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, recently announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to entrectinib “for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies”

  10. Glenmark Pharmaceuticals To Initiate Clinical Study For GBR 1342, Second Investigational New Drug From Immuno-Oncology Portfolio
    5/15/2017

    Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) cleared the company's Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342, a humanized, bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies